LEO Pharma A/S is with preparations for a potential stock market listing this year, according to CEO Christophe Bourdon. The Danish pharmaceutical company has been engaging with prospective investors in recent months as part of its IPO preparations.

While specific valuation targets haven't been disclosed, the timing suggests LEO Pharma is positioning itself for what could be one of Europe's notable healthcare IPOs in 2025. The company, which specializes in dermatology and critical care treatments, has been privately held since its founding in 1908.

The move comes as the IPO market shows signs of thawing after years of limited activity. For LEO Pharma, going public would provide capital for research and development while giving early investors an exit opportunity. The company's leadership appears confident in market conditions despite ongoing economic uncertainty.